logo-loader
viewHemoGenyx Pharmaceuticals

HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors.

It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations with leading universities and pharmaceutical companies.

Dr Sandler says all is on track and work is “progressing successfully” towards  the goal of submitting an investigational new drug application to the US Food and Drug Administration for their CDX antibodies product.

Quick facts: HemoGenyx Pharmaceuticals

Price: 1.85 GBX

LSE:HEMO
Market: LSE
Market Cap: £7.35 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of HemoGenyx Pharmaceuticals named herein, including the promotion by the Company of HemoGenyx Pharmaceuticals in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: New 11-year supply deal for Sirius Minerals

Top stories from the Proactive Investors UK newsroom. Events group Live Company (LON:LVCG) has entered into an agreement with Nickelodeon to produce themed tours associated throughout the UK and Ireland. The tours will based around Nickelodeon brands, including Nick Jr. HemoGenyx...

on 12/6/19

2 min read